Login to Your Account



Clinic Roundup


Monday, May 14, 2012
• Cytochroma Ltd., of Markham, Ontario, reported data from a 78-subject Phase IIb trial showing that CTAP101 capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage III or Stage IV chronic kidney disease and vitamin D insufficiency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription